Samsung Biologics
Samsung Biologics, a leading player in the pharmaceutical preparation manufacturing industry, is headquartered in Incheon, South Korea (KR). Founded in 2011, the company has rapidly established itself as a key provider of contract development and manufacturing services (CDMO) for biopharmaceuticals, focusing on monoclonal antibodies and other biologics.
With state-of-the-art facilities and a commitment to innovation, Samsung Biologics offers unique solutions that streamline the drug development process, ensuring high-quality production standards. The company has achieved significant milestones, including the expansion of its manufacturing capacity and the successful completion of numerous projects for global clients. Recognised for its excellence, Samsung Biologics continues to strengthen its market position, contributing to advancements in the biopharmaceutical sector.
+19 vs industry average
Samsung Biologics’s score of 57 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Samsung Biologics?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Samsung Biologics's reported carbon emissions
Samsung Biologics, a Pharmaceutical Preparation Manufacturing company based in Korea (KR), is actively working towards reducing its environmental impact.
Carbon Emissions Data:
- 2024: The company reported a total of approximately 636,209,000 kg CO2e. This breakdown includes:
- Scope 1: Approximately 71,971,718 kg CO2e.
- Scope 2 (market-based): Approximately 115,827,854 kg CO2e.
- Scope 3: Approximately 448,410,157 kg CO2e, with purchased goods and services being the largest contributor.
- 2023: Total emissions for 2023 were approximately 696,378,000 kg CO2e. This consisted of Scope 1 at roughly 69,262,496 kg CO2e, Scope 2 (market-based) at approximately 113,313,391 kg CO2e, and Scope 3 at around 513,803,084 kg CO2e.
- 2022: The total emissions for 2022 were approximately 946,205,000 kg CO2e, comprising Scope 1 at approximately 54,575,447 kg CO2e, Scope 2 (market-based) at approximately 99,917,630 kg CO2e, and Scope 3 at approximately 791,712,059 kg CO2e.
- 2021: In 2021, total emissions were approximately 1,061,292,000 kg CO2e, including Scope 1 at approximately 44,063,000 kg CO2e, Scope 2 at approximately 86,867,000 kg CO2e, and Scope 3 at approximately 917,229,000 kg CO2e.
- 2020: Total emissions for 2020 amounted to approximately 124,807,000 kg CO2e for Scope 1 and 2 combined, with Scope 1 at approximately 41,793,000 kg CO2e and Scope 2 at approximately 83,014,000 kg CO2e. Scope 3 emissions were approximately 64,172,000 kg CO2e.
- 2019: Scope 1 and 2 emissions for 2019 totalled approximately 119,791,000 kg CO2e, with Scope 1 at around 40,166,000 kg CO2e and Scope 2 at approximately 79,625,000 kg CO2e. Scope 3 data was not disclosed for this year.
- 2018: Scope 1 and 2 emissions for 2018 were approximately 116,579,000 kg CO2e, with Scope 1 at about 40,967,000 kg CO2e and Scope 2 at approximately 75,612,000 kg CO2e. Scope 3 data was not disclosed.
- 2017: In 2017, Scope 1 and 2 emissions totalled approximately 85,314,000 kg CO2e, with Scope 1 at roughly 29,587,000 kg CO2e and Scope 2 at approximately 55,727,000 kg CO2e. Scope 3 data was not disclosed.
Climate Commitments and Reduction Targets:
Samsung Biologics has set a clear objective to achieve Net Zero emissions by 2050 or earlier. To support this overarching goal, the company has established key milestones:
- Direct Emissions (Scope 1): A reduction of 32% by 2030 and 62% by 2040, using 2022 as the baseline year.
- Supplier Emissions (Scope 3): A reduction target of 36% by 2030 and 73% by 2040, also with a 2022 baseline.
- Long-term Target: The company is committed to Net Zero across all scopes by 2050.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Samsung Biologics’s Climate Goals (2030 & 2050)
3 goals2030
62% reduction
As part of the company’s mission to deliver net zero by 2050 or earlier, Samsung Biologics established new milestones: to cut 32% of direct…
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 3 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
11 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Samsung Biologics
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project